3 news items
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
ATXI
FBIO
16 May 24
receptor ("AR") which leads to production of a mutant polyglutamine ("polyQ") AR protein that forms aggregates responsible for muscular atrophy focused
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
ATXI
FBIO
25 Mar 24
in the androgen receptor ("AR") which leads to production of a mutant polyglutamine ("polyQ") AR protein that forms aggregates responsible
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
ATXI
FBIO
11 Mar 24
with high predictability of response in humans MIAMI, March 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics
- Prev
- 1
- Next